Recruiting
Phase 1

LY4329090

Sponsor:

Eli Lilly and Company

Code:

NCT07808073

Conditions

Obesity

Overweight

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

LY4329090

Placebo

Study Details

Brief summary:

The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Study participants will be in one of 2 parts. For each participant in Part A, the study will last about 10 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 5 nights along with 5 outpatient visits to the CRU. For each participant in Part B, the study will last about 21 weeks and will include 4 stays totaling 11 nights along with 14 outpatient visits to the CRU.

Conditions

Obesity

Overweight

Study ID

NCT07808073

Start date

Sep 22, 2026

Status verified date

Oct, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent.
  • Are overtly healthy with no comorbidities related to body mass index (BMI).
  • Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m², inclusive.
  • Have had a self-reported stable weight for 3 months prior to screening.

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders.
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys.
  • Have either

  • ongoing asymptomatic bradycardia defined as less than 50 beats per minute at screening visit
  • electrocardiogram (ECG) findings at screening visit of second-degree atrioventricular block or higher, or
  • history of symptomatic bradycardia with uncorrected etiology, including diagnosis of sick sinus syndrome.
  • Have an abnormal blood pressure and/or pulse rate at screening.
  • Have an obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.
  • Have any of the following:

  • a diagnosis of hypocalcemia or hypercalcemia, or
  • confirmed abnormal laboratory values for calcium and serum phosphorus.
  • Have a known, clinically significant gastric emptying abnormality, have undergone weight loss surgery, or have had endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.
  • Have been diagnosed with type 1 or type 2 diabetes mellitus or have glycated hemoglobin A1c (HbA1c) greater than or equal to (≥) 6.5 percent (%) or 48 millimoles per mole (mmol/mol) at screening.
  • Have a history or presence of psychiatric disorders, within the last 2 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
  • Have taken any glucose-lowering medications, including insulin, in the past 3 months before screening.
  • Have received any drugs from the incretins class within 90 days prior to screening.
  • Have been treated within 3 months prior to screening or plan to be treated with prescription medications that promote weight loss.
  • Intend to use any weight loss medications during study participation.
  • Prior (within 6 months) or planned (during the study) device-based treatment use for obesity.

Study Design

Enrollment

184 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: LY4329090 Part A

Participants will receive LY4329090 administered subcutaneously (SC)

experimental: Placebo Part A

Participants will receive placebo administered SC

experimental: LY4329090 Part B

Participants will receive LY4329090 administered SC

placebo comparator: Placebo Part B

Participants will receive placebo administered SC

Interventions

LY4329090

Administered SC

Placebo

Administered SC

Primary outcome measure

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: End of Study (Week 28) ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Fortrea Clinical Research Unit

Recruiting

Daytona Beach, Florida, United States, 32117

Contacts

386-366-6417

Principal Investigator:

Chiamaka Iheme

Fortrea Clinical Research Unit

Recruiting

Dallas, Texas, United States, 75247

Contacts

866-429-3700

Principal Investigator:

Gene Voskuhl

More Information

Sponsor

Eli Lilly and Company

Last update posted

Oct 8, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-09. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-10-08. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.